High-fidelity and Network-based Spatio-temporal Mathematical Models of Alzheimer's Disease Progression and their Validation Against PET-SUVR Imaging Data
Beatrice Caon, Mattia Corti, Francesca Bonizzoni, Paola F. Antonietti
TLDR
This paper compares high-fidelity 3D and network-based spatio-temporal models for Alzheimer's disease progression, validated with PET-SUVR data.
Key contributions
- Introduces a framework for modeling amyloid-beta and tau protein dynamics in AD.
- Compares high-fidelity 3D patient-specific models with reduced network-based models.
- Validates both modeling approaches against PET-SUVR clinical imaging data.
- Shows 3D models are more accurate but computationally expensive, while network models are cheaper.
Why it matters
This work offers valuable insights into modeling Alzheimer's disease progression, comparing accuracy and computational cost. It highlights the trade-offs between detailed 3D simulations and efficient network-based approaches, guiding future research in AD modeling.
Original Abstract
Alzheimer's disease is the most common neurodegenerative disorder. Its pathological development is connected with the misfolding and accumulation of two toxic proteins: amyloid-beta and tau proteins. Mathematical models provide a valuable quantitative tool for monitoring disease progression. In this work, we proposed and compare a novel framework where the spatio-temporal dynamics of amyloid-beta and tau proteins is modeled based on employing either three-dimensional patient-specific geometries or through reduced network-based models defined on the brain connectome. More specifically, a high-fidelity biophysical model is proposed on three-dimensional brain geometries reconstructed from magnetic resonance imaging, whereas a network-based reduced formulation is defined on the brain connectome. For both approaches, a suitable numerical discretisation is proposed. A sensitivity analysis is presented to quantify the influence of model parameters on protein concentration patterns as well as compare the quality of the predictions. For both approaches, the results are validated against PET-SUVR clinical data using 18FAZD4694 for amyloid-beta and 18FMK6240 for tau protein. The results indicate that the three-dimensional model provides the most accurate and biologically consistent description of the disease progression, but remains computationally demanding. On the other hand, the reduced graph-based model is cheaper, but it is not always able to achieve reliable results.
📬 Weekly AI Paper Digest
Get the top 10 AI/ML arXiv papers from the week — summarized, scored, and delivered to your inbox every Monday.